<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190303</url>
  </required_header>
  <id_info>
    <org_study_id>UoL001430 - 4069</org_study_id>
    <nct_id>NCT04190303</nct_id>
  </id_info>
  <brief_title>BIGlobal Intervention Study: Improving Diagnosis and Management of Suspected Brain Infections Globally</brief_title>
  <official_title>NIHR Global Health Research Group on Brain Infections Study: Establishing a Standard Care Package to Improve Diagnosis and Early Hospital Management of Patients With Suspected Acute Brain Infections in Low and Middle Income Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christian Medical College, Vellore, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malawi College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patients with suspected brain infections pose major challenges to low and middle&#xD;
      income countries, including their disproportionately high burden, diverse causes with&#xD;
      inadequate surveillance, requirement for invasive and expensive tests, and the difficulty of&#xD;
      management without a clear diagnosis. This is all compounded by resource and system&#xD;
      constraints. Few studies have attempted to improve the care of these people in&#xD;
      resource-limited settings.&#xD;
&#xD;
      Aim: This study sets out to improve the diagnosis and early management of people with&#xD;
      suspected acute (&lt;28 days of symptoms) brain infections in low and middle income countries,&#xD;
      using a coordinated thematic approach.&#xD;
&#xD;
      Outcomes: The primary outcome will be proportion of people with suspected acute brain&#xD;
      infection receiving a diagnosis. Secondary outcomes will include mortality, length of stay in&#xD;
      hospital, quality of life, degree of disability, and proportion having a lumbar puncture&#xD;
      test.&#xD;
&#xD;
      Participants: Children and adults with features consistent with an acute brain infection,&#xD;
      including meningitis and encephalitis, will be recruited at a variety of hospitals in Brazil,&#xD;
      India and Malawi.&#xD;
&#xD;
      Study procedures: An assessment of current practice and capabilities at each hospital,&#xD;
      including patient and sample journey observations and interviews with healthcare staff, will&#xD;
      identify barriers to optimal care. Using this, a sustainable pragmatic multi-component&#xD;
      intervention will be produced, with components modifiable to each hospital's needs. Outcomes&#xD;
      will be reassessed post-intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological diagnosis</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>Proportion of patients achieving microbiological diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Syndromic diagnosis</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>Proportion of patients achieving syndromic diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion receiving, and time to lumbar puncture</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>Proportion of study participants receiving a lumbar puncture, and time to lumbar puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion having appropriate cerebrospinal fluid investigations</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>All of: cell count, total and differential; CSF protein concentration; CSF glucose concentration; paired serum/blood glucose concentration; microscopy and culture for bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 30 days</time_frame>
    <description>All-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>Duration of hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to appropriate empirical therapy</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>Time to appropriate empirical anti-infective therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to appropriate definitive therapy</measure>
    <time_frame>During hospital admission, or at 30 days if participant still in hospital</time_frame>
    <description>Time to appropriate definitive anti-infective therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>At hospital discharge, or at 30 days if participant still in hospital</time_frame>
    <description>Using EuroQol EQ-5D questionnaires scoring 5 domains at levels 1-3 each, and an overall health state from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>At 30 days after presentation to hospital</time_frame>
    <description>Using EuroQol EQ-5D questionnaires scoring 5 domains at levels 1-3 each, and an overall health state from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liverpool Outcome Score</measure>
    <time_frame>At hospital discharge, or at 30 days if participant still in hospital</time_frame>
    <description>Score measuring neurological function after brain infection, reporting a lowest score of 15 domains between 2 and 5, and a total score with range 33-75.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liverpool Outcome Score</measure>
    <time_frame>At 30 days after presentation to hospital</time_frame>
    <description>Score measuring neurological function after brain infection, reporting a lowest score of 15 domains between 2 and 5, and a total score with range 33-75.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Meningitis</condition>
  <condition>Encephalitis</condition>
  <condition>Abscess Brain</condition>
  <arm_group>
    <arm_group_label>Baseline (pre-intervention)</arm_group_label>
    <description>Current routine care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-intervention</arm_group_label>
    <description>Care following development and delivery of the system-level intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pragmatic, multi-component package</intervention_name>
    <description>This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff</description>
    <arm_group_label>Post-intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to a study hospital with symptoms and/or signs suggestive of an acute&#xD;
        brain infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults, infants and children presenting to a study hospital with symptoms and/or signs&#xD;
             suggestive of acute brain infection, which could be suspected encephalitis, suspected&#xD;
             meningitis, or alternative features raising suspicion of brain infection.&#xD;
&#xD;
          2. Symptom duration of less than 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neonates, i.e. children under the age of 28 days.&#xD;
&#xD;
          2. People with pre-existing indwelling ventricular devices (e.g. extra-ventricular&#xD;
             drains, ventriculo-peritoneal shunts) or other implants in contact with the meninges&#xD;
             or brain (e.g. deep brain stimulators).&#xD;
&#xD;
          3. People without an indwelling device, having undergone neurosurgical procedures within&#xD;
             the preceding 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Solomon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Infection &amp; Global Health, University of Liverpool</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhagteshwar Singh, MBChB</last_name>
    <phone>+441517957577</phone>
    <email>bsingh@liverpool.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>FioCruz</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Franca</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Mental Health and Neurosciences</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Desai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Rupali</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malawi Liverpool Wellcome Trust</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Cornick</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>India</country>
    <country>Malawi</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Tom Solomon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

